European Pharmaceutical Review

MAY 2, 2023

We believe that this acquisition will enable us to deliver greater value to patients with ocular diseases at high risk of blindness,” stated Naoki Okamura, President and CEO of Astellas. Avacincaptad pegol is forecasted to achieve sales of $1.09 billion in 2028, according to GlobalData’s Pharma Intelligence Center.

Food and Drug Administration 52

Food and Drug Administration Pharma FDA Sales 52

Pharmaceutical Technology

MARCH 30, 2023

On the same day, researchers presented new interim data from the Phase III RUBY trial of GSK’s PD-1 antibody Jemperli (dostarlimab) in patients with primary advanced or recurrent endometrial cancer. In 2022, the company reported Keytuda sales of $20.9 billion in 2028. billion in its FY 2022 results.

Food and Drug Administration 52

Food and Drug Administration FDA Sales Food 52

Pharmaceutical Technology

AUGUST 16, 2022

In 2019, Daiichi Sankyo entered a global development and commercialisation agreement with AstraZeneca for Daiichi Sankyo’s lead antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), in a deal worth $6.9bn. months compared with patients treated with standard-of-care chemotherapy.

Food and Drug Administration 59

Food and Drug Administration Sales Patients Food 59

Pharmaceutical Technology

SEPTEMBER 2, 2022

This is a result of intensive research efforts that have produced regimens that have prolonged patient survival, most of which are a combination of a proteasome inhibitor + an immunomodulatory drug (ie. billion global sales expected by 2028, followed by Tecvayli with $2.6bn, which would mark a huge win for J&J in the MM space.

Food and Drug Administration 59

Food and Drug Administration FDA Sales Physicians 59